825780

Drug Profile

825780

Alternative Names: GW-825780; HIV DNA vaccine - GlaxoSmithKline/PowderMed; Therapeutic HIV DNA vaccine - GlaxoSmithKline/PowderMed

Latest Information Update: 16 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; PowderMed
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Sep 2005 Profile reviewed with information available at the BIO-2005 conference
  • 30 Nov 2004 Phase-I clinical trials in HIV infections treatment in England (Intradermal)
  • 03 Jun 2004 PowderMed, an independent company spun off from Chiron Vaccines is now developing the HIV DNA vaccine in partnership with GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top